Authors
Yichen Tian, Yanan Li, Mengyu Cao, Qinao Wang, Mengyuan Xu, Wenjie Li, Hailin Cong, Bing Yu
Published in
Small (Weinheim an der Bergstrasse, Germany). Pages e75785. Sep 16, 2026. Epub Sep 16, 2026.
Abstract
Conventional cancer therapies are often limited by inadequate drug accumulation in tumors, drug resistance, and systemic toxicity. Cell-penetrating peptides (CPPs) offer a promising strategy to enhance intracellular drug delivery. In this study, we designed a novel tumor-penetrating peptide, P3 (sequence: Trp-Lys-Ala-Ser-Cys), which demonstrated exceptional transmembrane efficiency with a broad-spectrum penetration profile across various tumor cell lines (including HeLa, HGC-27, and A549 etc.). Notably, it achieved an internalization rate of 47.4% in A549 cells within 15 min. This peptide was further engineered into an amphiphilic polymer, P3-Mal-PEG-PCL, which self-assembled into pH-responsive micelles. Doxorubicin (DOX) was encapsulated within these micelles to form DOX@P3P, which was subsequently coated with hyaluronic acid (HA) to create the final actively targeted nanoparticles, DOX@P3P@HA (PHA NPs), leveraging the cluster of differentiation 44 (CD44) receptor overexpression on cancer cells. The PHA NPs displayed excellent biosafety, colloidal stability, and improved drug distribution. In a murine tumor model, treatment with PHA NPs resulted in a remarkable 76.6% reduction in tumor volume, underscoring its potent antitumor efficacy and highlighting its potential as a robust platform for targeted cancer chemotherapy.
PMID:
42747344
Bibliographic data and abstract were imported from PubMed on 16 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0